Imagine being able to determine if a hepatitis C treatment has worked in just 4 weeks instead of waiting a full 12 weeks. This game-changing discovery could revolutionize how we manage this disease. But here's where it gets controversial: could this faster assessment lead to over-treatment or unnecessary anxiety for patients? Let’s dive in.
At the 2025 American Association for the Study of Liver Diseases (AASLD) meeting, Dr. Marc Bourlière from Hôpital Saint Joseph in Marseilles, France, presented findings that challenge traditional timelines for assessing sustained virological response (SVR) in hepatitis C virus (HCV) treatment. According to a four-trial analysis, evaluating SVR at 4 weeks (SVR4) after treatment was just as predictive of a cure as the standard 12-week assessment (SVR12), regardless of whether patients had previously used direct-acting antivirals (DAAs).
Why does this matter? For starters, a shorter assessment period could significantly reduce the number of patients lost to follow-up—a common challenge in HCV care. In the POLARIS studies, which compared 8-week and 12-week treatments with sofosbuvir/velpatasvir/voxilaprevir (Vosevi) and sofosbuvir/velpatasvir (Epclusa), 1,009 patients achieved SVR4. Of those, 1,001 also achieved SVR12, resulting in a 99.2% positive predictive value (PPV) for SVR4. Even more striking, none of the 23 patients who didn’t achieve SVR4 were cured by 12 weeks, giving SVR4 a 100% negative predictive value (NPV) for SVR12.
And this is the part most people miss: SVR4 isn’t just a time-saver—it’s a powerful tool for clinicians. As Dr. Bourlière explained, ‘You can really use the SVR4 post-treatment as a good tool for assessing the fact that your patient is cured.’ This is especially critical for high-risk populations, where early detection of relapse or non-response can prompt timely re-treatment, potentially preventing further transmission.
But let’s pause for a moment. Is SVR4 too good to be true? While the data is compelling, some might argue that relying on a 4-week assessment could lead to false confidence or overlook rare late relapses. For instance, of the 31 patients who relapsed in the trials, only 8 (26%) had achieved SVR4. Additionally, nearly three-quarters of relapsed patients were male, and 61% had HCV genotype 1, raising questions about whether certain demographics might benefit less from this approach.
Interestingly, SVR4’s accuracy held up regardless of treatment duration. In the 8-week POLARIS-2 and -3 trials, SVR4 had a 99.1% PPV and 100% NPV, while in the 12-week POLARIS-1 and -4 trials, it achieved a 99.3% PPV and 100% NPV. This consistency suggests that SVR4 could be a reliable measure across different treatment regimens.
However, Dr. Bourlière cautioned that while HCV treatments are highly effective, vulnerable populations often fail to return for 12-week assessments. ‘If you are treating patients at high risk of transmission, don’t let them go away,’ he urged. ‘Keep them on surveillance, because you need to assess if there is relapse, if there are reinfections, and then re-treat these patients.’
The 2025 Hepatitis C Point of Care Test and Treat Algorithm from AASLD and the Infectious Diseases Society of America already endorses SVR4 as an acceptable cure measure for patients without cirrhosis or prior DAA treatment. But here’s the question: Should SVR4 become the new standard, or is it too soon to abandon the tried-and-true 12-week assessment?
What do you think? Is SVR4 a breakthrough worth adopting widely, or are there still too many unknowns? Share your thoughts in the comments—let’s spark a conversation!
